CD47 and neoplasm: In hSIRPα/CD47 transgenic mice, NILK-2401 treatment at 30 mg/kg IP twice/week significantly suppressed tumor growth of MC38-hCEACAM5/hCD47, with a TGI of 84.3% at d22 (i.e., 1st day of euthanasia due to tumor volume >1500 mm3; Figures 6D–F).